Co-Diagnostics (DE:C970)
NASDAQ:C970
Want to see DE:C970 full AI Analyst Report?
C970 Stock Chart & Stats
€0.26
-€0.13(-13.68%)
At close: 4:00 PM EST
€0.26
-€0.13(-13.68%)
Day’s Range― - ―
52-Week Range€5.16 - €36.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€4.33M
Enterprise Value-€8.91M
Total Cash (Recent Filing)€11.88M
Total Debt (Recent Filing)€1.24M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.89
Shares Outstanding3,602,465
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.33
Price to Sales (P/S)16.13
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.25Price Target Upside1533.02% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-10.51
Revenue Forecast (FY)€498.34K
Bulls Say, Bears Say
Bulls Say
Intellectual Property & Proprietary CoPrimer PlatformInternational patent grants for core Co-Dx PCR components and the proprietary CoPrimer platform meaningfully strengthen product defensibility. Strong IP supports licensing, deters competitors, aids reimbursement/regulatory positioning, and preserves long-term commercial upside across markets.
India Manufacturing License And Larger South Asia Addressable MarketLocal manufacturing authorization in India and expanded commercial territory materially improves go-to-market economics and market access. It reduces supply chain risk, lowers unit costs, and positions the company to capture high TB incidence demand, supporting sustainable revenue scaling in South Asia.
CoMira JV Advancing Local Manufacturing In MENAProgress toward domestic manufacturing via the CoMira JV creates a durable competitive advantage in MENA by enabling local supply, cost competitiveness, and preferential procurement. Regional production reduces regulatory friction and supports longer-term commercial contracts and market share gains.
Bears Say
Sharp Revenue CollapseAn ~85% revenue drop dramatically weakens the company's ability to leverage fixed costs and fund commercialization. Persistent low top-line makes multi-year profitability unlikely without material uptake or new revenue streams, increasing execution risk for product launches and regulatory investments.
Material Cash Burn And Depleted Cash BalanceSustained operating cash outflows and a ~60% reduction in cash reserves constrain runway for clinical studies, regulatory submissions, and commercialization. The company will likely need external financing, heightening dilution or covenant risk and potentially delaying strategic initiatives.
Platform Largely Pre-commercial And Regulatory-dependentReliance on pending regulatory approvals and limited current commercial traction means future revenues depend on successful submissions, local clearances, and partner rollouts. Delays or unfavorable regulatory outcomes could materially postpone revenue realization and strain resources.
Co-Diagnostics News
C970 FAQ
What was Co-Diagnostics’s price range in the past 12 months?
Co-Diagnostics lowest stock price was €5.16 and its highest was €36.00 in the past 12 months.
What is Co-Diagnostics’s market cap?
Co-Diagnostics’s market cap is €4.33M.
When is Co-Diagnostics’s upcoming earnings report date?
Co-Diagnostics’s upcoming earnings report date is May 07, 2026 which is in 19 days.
How were Co-Diagnostics’s earnings last quarter?
Co-Diagnostics released its earnings results on Mar 31, 2026. The company reported -€13.888 earnings per share for the quarter, missing the consensus estimate of -€3.058 by -€10.83.
Is Co-Diagnostics overvalued?
According to Wall Street analysts Co-Diagnostics’s price is currently Undervalued.
Does Co-Diagnostics pay dividends?
Co-Diagnostics does not currently pay dividends.
What is Co-Diagnostics’s EPS estimate?
Co-Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Co-Diagnostics have?
Co-Diagnostics has 3,602,465 shares outstanding.
What happened to Co-Diagnostics’s price movement after its last earnings report?
Co-Diagnostics reported an EPS of -€13.888 in its last earnings report, missing expectations of -€3.058. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Co-Diagnostics?
Currently, no hedge funds are holding shares in DE:C970
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Co-Diagnostics
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
C970 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed clear strategic and operational progress — NASDAQ relisting, CoSara manufacturing license and regional expansion, CoMira JV advancement, strengthened IP, progress in clinical programs (1,200+ enrollments) and AI development — but these positives are offset by significant financial headwinds: an ~84.6% revenue decline driven by lower grant income, a large $18.9M noncash impairment that increased operating expenses, a widened GAAP net loss ($46.9M) and a ~60% reduction in cash to $11.9M. Management highlighted cost discipline and improved adjusted EBITDA excluding impairment, and articulated near-term commercialization paths (notably TB in India expected by Q3 2026), yet the company faces continued cash burn and will need to secure additional financing or strategic transactions to execute growth plans. Overall, the call signals meaningful operational milestones but material financial and execution risks remain.View all DE:C970 earnings summariesC970 Stock 12 Month Forecast
Average Price Target
€4.25
▲(1533.02% Upside)
Sintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Allurion Technologies
―
Heart Test Laboratories, Inc.
―
Options Prices
Currently, No data available
---